Harmful alcohol consumption remains a major public health issue and is increasingly assessed using laboratory biomarkers in both clinical and forensic settings. Because test results may influence medical decisions, fitness-to-drive assessments, occupational evaluations in safety-sensitive professions, and legal outcomes, biomarkers used to assess alcohol consumption should provide reliable, accurate, and internationally comparable results.
This article reviews the current landscape of alcohol biomarkers and highlights the importance of analytical standardization and traceability. Particular emphasis is placed on carbohydrate-deficient transferrin (CDT), a biomarker specifically associated with chronic excessive alcohol consumption. Extensive work by the IFCC Working Group on CDT Standardization led to the development of an IFCC-recognized reference measurement procedure (RMP) and its subsequent recognition by the Joint Committee for Traceability in Laboratory Medicine (JCTLM).
As a result, CDT-IFCC is currently the only alcohol biomarker supported by an internationally recognized framework for standardization and traceability, enabling consistent, comparable, and clinically reliable results.
Test associated with this resource
Related instruments
The compact and affordable automation of Capillary Electrophoresis.
Evolution makes the difference.
A concentrate of Sebia’s expertise in a high throughput instrument.
Capillary Electrophoresis solution to meet your high capacity needs.
Discover more resources on Chronic Alcohol Abuse
Comprehensive data analysis and interpretation software for Sebia assays on electrophoresis instruments.
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country. Please contact your local Sebia representative. Information intended for healthcare professionals. Carefully read the instructions in the reagent package inserts and instrument manuals.